Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02343042
Title Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Indications

multiple myeloma

Therapies

Bortezomib

Dexamethasone + Selinexor

Pomalidomide

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.